When a newly licensed PMHNP asks "can I open my own practice?", the answer almost always starts with "it depends on your state." That's not a dodge - it's the most accurate thing anyone can tell you. Nurse practitioner practice authority in the United States exists on a spectrum, and where your state sits on that spectrum changes your launch timeline, your startup costs, your administrative overhead, and in some cases whether you can prescribe controlled substances from day one.
Full Practice Authority, or FPA, is the designation the American Association of Nurse Practitioners uses to describe states where NPs can evaluate, diagnose, order tests, and prescribe - including Schedule II–V controlled substances - without physician oversight. As of 2026, more than 27 states and territories have achieved FPA. But what that means operationally varies more than most practitioners realize.
"FPA doesn't mean you're automatically set up to prescribe on day one. It means you don't need a collaborating physician. The DEA, your state board, and your EHR all still have their own requirements."
The Three Tiers of Practice Authority
The AANP categorizes state NP practice law into three tiers. Understanding which tier your state falls into is the first task of Month 1 in your 90-day launch sequence - because it determines what you need to obtain before you can see a single patient.
Full Practice Authority (FPA)
NPs may practice independently without any collaborative, supervisory, or consultative agreement with a physician. This is the standard most aligned with the Institute of Medicine's recommendation that NPs practice to the full extent of their education and training. In FPA states, your business entity, NPI, DEA registration, and state license are the only infrastructure gates between you and an independent panel.
Reduced Practice Authority
NPs can perform most functions independently but have at least one element of practice that requires a collaborative agreement - most commonly prescribing Schedule II controlled substances. Reduced practice states often require the agreement to be documented and on file, but may not require active chart co-signing or supervision of clinical decisions.
Restricted Practice Authority
NPs must work under the active supervision or oversight of a physician for all or most clinical activities. Agreements are typically formal, often require the physician to review a percentage of charts, and the physician may carry liability exposure for your practice decisions. These arrangements cost money - market rates for collaborating physician agreements range from $500 to $2,500 per month depending on specialty and state.
What this means for your budget in Month 1
If you're in a restricted or reduced practice state, your startup cost calculation must include collaborative agreement fees. Budget $6,000–$30,000 annually for the agreement alone. This is not optional - practicing without the required agreement exposes your license to disciplinary action and voids your malpractice coverage.
FPA States as of 2026
The following states and territories have enacted full practice authority legislation. Note that some states granted FPA with transition periods - meaning new graduates must complete a supervised practice requirement (typically 2–3 years) before practicing fully independently. These are marked below.
| State / Territory | FPA Status | Transition Period | PMHNP Notes |
|---|---|---|---|
| Alaska | Full FPA | None | No restrictions on prescribing Schedule II–V |
| Arizona | Full FPA | None | Independent prescriptive authority; DEA registration required |
| Colorado | Full FPA | None | Full independent practice; strong mental health market |
| Connecticut | Full FPA | 2 yrs supervised | New NPs must complete transition period post-licensure |
| Hawaii | Full FPA | None | Independent authority; certificate of prescriptive authority required |
| Idaho | Full FPA | None | No collaborative agreement needed |
| Iowa | Full FPA | None | Full practice and prescriptive authority |
| Maine | Full FPA | 2 yrs supervised | Transition to practice requirement for new NPs |
| Maryland | Full FPA | None | Full independent practice; significant telehealth market |
| Minnesota | Full FPA | None | Independent practice; collaborative agreement optional |
| Montana | Full FPA | None | Early FPA adopter; full prescriptive authority |
| Nevada | Full FPA | None | Full independent practice; growing telehealth presence |
| New Hampshire | Full FPA | None | No collaborative agreement required |
| New Mexico | Full FPA | None | One of first FPA states; CNP and CNS both covered |
| North Dakota | Full FPA | None | Full prescriptive authority including Schedule II |
| Oregon | Full FPA | None | Strong behavioral health infrastructure; FPA fully enacted |
| Rhode Island | Full FPA | None | Independent practice authority fully enacted |
| Vermont | Full FPA | None | No supervision requirement; full prescriptive authority |
| Virginia | Full FPA | 5 yrs supervised | Long transition period; plan your launch timeline accordingly |
| Washington | Full FPA | None | Full independent practice; active PMHNP market |
| Wyoming | Full FPA | None | No collaborative agreement required |
| Texas | Restricted | N/A | Physician delegation required; costly agreements; no FPA |
| Florida | Restricted | N/A | Supervision agreement required; physician co-signing common |
| California | Reduced | 3 yrs supervised | Transition to practice law enacted 2023; full FPA pending years of supervised practice |
| New York | Reduced | 3,600 hrs supervised | Collaborative agreement required until supervised hour threshold met |
This table is illustrative, not exhaustive - always verify current law with your state board of nursing before launching. State legislatures continue to update practice authority laws, and implementation timelines matter as much as the headline legislation.
How Practice Authority Affects Month 1 of Your 90-Day Sequence
Your practice authority tier directly determines what you need to accomplish in the first 30 days of your launch sequence. In FPA states with no transition period, Month 1 is clean: file your entity, apply for your NPI Type 2, initiate CAQH, and begin your DEA registration. No additional agreements needed.
In restricted and reduced practice states, Month 1 has an additional critical task: securing a collaborating physician agreement before you can practice. This is often where practitioners lose weeks - and sometimes months - because they don't start sourcing a collaborator early enough.
Month 1 task list by practice authority tier
- FPA (no transition): File entity → NPI Type 2 → CAQH → DEA registration → state prescriptive authority certificate (if applicable)
- FPA (with transition): Same as above, plus confirm you have met the supervised hours requirement or identify a supervising arrangement for the transition period
- Reduced practice: Same as FPA plus source and execute a collaborative agreement covering restricted prescribing functions before opening your panel
- Restricted practice: All of the above plus a physician supervision agreement covering clinical oversight, chart review schedule, and liability allocation - executed before your first patient visit
DEA Registration and FPA: What's Separate
One of the most persistent misconceptions among NPs preparing to launch is the belief that FPA automatically resolves DEA prescribing authority. It does not. FPA removes the state-level physician oversight requirement. The DEA is a federal agency and issues its own registration independently of state practice authority law.
To prescribe controlled substances - including benzodiazepines, stimulants for ADHD, and buprenorphine products commonly used in psychiatric and addiction practices - you must hold an active DEA registration in the state where you practice. For PMHNPs operating in multiple states or via telehealth across state lines, this means a DEA registration per state, or use of the DEA's telemedicine-specific provisions.
DEA registration requires your state NP license to be active and in good standing. It also requires you to have an active business address - which means your entity must be filed and your practice address confirmed before you can submit the DEA application. In the 90-day sequence, this means DEA registration falls in late Month 1 or early Month 2, after your entity and license details are confirmed.
"The most common DEA delay we see: practitioners apply before their entity address is finalized. The DEA application is rejected. They reapply. They lose 3–4 weeks."
PMHNP-Specific Considerations by State
PMHNPs face additional nuances that general FPA discussions often miss. The ability to prescribe psychiatric medications - antipsychotics, mood stabilizers, stimulants, benzodiazepines - means that PMHNPs in restricted or reduced practice states face a higher practical burden from collaborative agreement requirements than, say, a family NP.
A family NP in a reduced practice state may have their prescribing authority restricted only for Schedule II opioids - a relatively narrow constraint on their practice scope. A PMHNP in the same state may find that the same agreement restricts stimulant prescribing (Schedule II) and benzodiazepine prescribing (Schedule IV), two of the most commonly prescribed medication classes in outpatient psychiatry.
Additionally, some state Medicaid programs have separate credentialing requirements for behavioral health providers that don't map cleanly to the NP license tier. Before accepting Medicaid patients, confirm with your state Medicaid program that your license type is credentialed as a behavioral health provider, not just a primary care provider - because reimbursement rates and covered services differ.
Finally, if you plan to offer medication-assisted treatment (MAT) for opioid use disorder using buprenorphine products, the federal X-waiver requirement was eliminated in 2023 - but state-level prescribing protocols and collaborative agreement requirements may still apply in restricted practice states. Verify with your state board before treating OUD patients independently.
Emmanuel AJAO
Emmanuel AJAO is the founder and Chief Editor of goCorporate™. He has guided hundreds of licensed clinicians through the process of launching independent practices - from entity formation and credentialing through to patient acquisition and post-launch optimisation.